Publications by authors named "Jasmine Prevost"
Neurooncol Adv
August 2021
Article Synopsis
- Glioblastoma (GBM) employs immune suppression mechanisms like PD-L1 expression, and prior treatments targeting PD-1 didn’t show effectiveness; avelumab is a new PD-L1 targeting antibody capable of enhancing immune response.
- A phase II study added avelumab (10 mg/kg IV every two weeks) to the standard treatment for newly diagnosed GBM, focusing on safety and evaluating progression-free survival (PFS) and overall survival (OS).
- Out of 30 patients, 23.3% showed a positive response, with median PFS of 9.7 months and OS of 15.3 months, but the study revealed no new safety concerns or significant survival benefits from adding avelumab.
